Patents by Inventor Ivan N Rich
Ivan N Rich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7989178Abstract: A system combining a clonogenic differentiation assay with an instrument-based ATP bioluminescence proliferation assay to produce a standardized colony-forming stem and progenitor cell potency assay is provided.Type: GrantFiled: June 6, 2008Date of Patent: August 2, 2011Assignee: Hemogenix, Inc.Inventor: Ivan N. Rich
-
Patent number: 7883861Abstract: The present invention relates generally to kits that provide reagent mixes and instructions for the use thereof, in performing high-throughput assay methods that determine the proliferative status of isolated target cell populations. The methods measure the luminescent output derived from the intracellular ATP content of incubated target cells, and correlate the luminescence with the proliferative status of the cells. The present invention further relates to kits that provide reagent mixes and instructions for high-throughput assays methods for screening compounds that may modulate the proliferative status of a target cell population. The kits of the present invention and methods therein described may be used for determining the proliferative status of any isolated cell line or type. The kits and methods of the present invention address the need for rapid assays that determine the proliferative status of isolated hematopoietic stem and progenitor cells and of subpopulations of differentiated cells thereof.Type: GrantFiled: March 17, 2008Date of Patent: February 8, 2011Assignee: HemoGenix, Inc.Inventor: Ivan N. Rich
-
Patent number: 7709258Abstract: The present invention relates generally to high-throughput assay methods that determine the proliferative status of hematopoietic stem and progenitor cells. The present invention further relates to high-throughput assays for screening compounds that modulate the growth of hematopoietic stem and progenitor cells and for identifying subpopulations thereof that are suitable for transplantation. The assay of the present invention is particularly useful for quality control and monitoring of the growth potential in the stem cell transplant setting and would provide improved control over the reconstitution phase of transplanted cells.Type: GrantFiled: March 17, 2008Date of Patent: May 4, 2010Assignee: HemoGenix, Inc.Inventor: Ivan N. Rich
-
Patent number: 7700354Abstract: The present invention relates generally to high-throughput assay methods that determine the proliferative status of hematopoietic stem and progenitor cells. The present invention further relates to high-throughput assays for screening compounds that modulate the growth of hematopoietic stem and progenitor cells and for identifying subpopulations thereof that are suitable for transplantation. The assay of the present invention is particularly useful for quality control and monitoring of the growth potential in the stem cell transplant setting and would provide improved control over the reconstitution phase of transplanted cells.Type: GrantFiled: March 17, 2008Date of Patent: April 20, 2010Assignee: HemoGenix, Inc.Inventor: Ivan N. Rich
-
Patent number: 7666615Abstract: The present invention relates generally to assays, methods, and kits that provide reagent mixes and instructions for determining the proliferative status of isolated target cell populations. The methods measure the luminescent output derived from the intracellular ATP content of incubated target cells, and correlate the luminescence with the proliferative status of the cells.Type: GrantFiled: November 17, 2006Date of Patent: February 23, 2010Assignee: HemoGenix, Inc.Inventor: Ivan N. Rich
-
Publication number: 20090298102Abstract: Cell potency assays for use with cell-based therapies, and specifically, with stem cell therapies, are provided. Cell potency assays for bone marrow cells, mobilized peripheral blood, and umbilical cord blood are provided.Type: ApplicationFiled: May 11, 2009Publication date: December 3, 2009Inventor: Ivan N. Rich
-
Publication number: 20090011446Abstract: A system combining a clonogenic differentiation assay with an instrument-based ATP bioluminescence proliferation assay to produce a standardized colony-forming stem and progenitor cell potency assay is provided.Type: ApplicationFiled: June 6, 2008Publication date: January 8, 2009Applicant: HemoGenix, Inc.Inventor: Ivan N. Rich
-
Publication number: 20080248503Abstract: The present invention relates generally to kits that provide reagent mixes and instructions for the use thereof, in performing high-throughput assay methods that provide a method of screening compounds for cytotoxicity or other effects on target cell populations of the lymphohematopoietic system, including specific lineages. The methods measure the luminescent output derived from the intracellular ATP content of incubated target cells, and correlate the luminescence with the proliferative status of the cells. The methods may be used to predict the effect of virtually any compound on the lymphohematopoietic system and may be performed on multiple species simultaneously, thereby providing valuable information regarding potential cytotoxicity prior to preclinical studies and especially, patient clinical trials. The methods also provide the ability to screen compounds early in the drug development profile.Type: ApplicationFiled: February 16, 2006Publication date: October 9, 2008Inventor: Ivan N. Rich
-
Publication number: 20080160544Abstract: The present invention relates generally to kits that provide reagent mixes and instructions for the use thereof, in performing high-throughput assay methods that determine the proliferative status of isolated target cell populations. The methods measure the luminescent output derived from the intracellular ATP content of incubated target cells, and correlate the luminescence with the proliferative status of the cells. The present invention further relates to kits that provide reagent mixes and instructions for high-throughput assays methods for screening compounds that may modulate the proliferative status of a target cell population. The kits of the present invention and methods therein described may be used for determining the proliferative status of any isolated cell line or type. The kits and methods of the present invention address the need for rapid assays that determine the proliferative status of isolated hematopoietic stem and progenitor cells and of subpopulations of differentiated cells thereof.Type: ApplicationFiled: March 17, 2008Publication date: July 3, 2008Applicant: HemoGenix, Inc.Inventor: Ivan N. Rich
-
Publication number: 20080160563Abstract: The present invention relates generally to high-throughput assay methods that determine the proliferative status of hematopoietic stem and progenitor cells. The present invention further relates to high-throughput assays for screening compounds that modulate the growth of hematopoietic stem and progenitor cells and for identifying subpopulations thereof that are suitable for transplantation. The assay of the present invention is particularly useful for quality control and monitoring of the growth potential in the stem cell transplant setting and would provide improved control over the reconstitution phase of transplanted cells.Type: ApplicationFiled: March 17, 2008Publication date: July 3, 2008Applicant: HemoGenix, Inc.Inventor: Ivan N. Rich
-
Publication number: 20080160564Abstract: The present invention relates generally to high-throughput assay methods that determine the proliferative status of hematopoietic stem and progenitor cells. The present invention further relates to high-throughput assays for screening compounds that modulate the growth of hematopoietic stem and progenitor cells and for identifying subpopulations thereof that are suitable for transplantation. The assay of the present invention is particularly useful for quality control and monitoring of the growth potential in the stem cell transplant setting and would provide improved control over the reconstitution phase of transplanted cells.Type: ApplicationFiled: March 17, 2008Publication date: July 3, 2008Applicant: HemoGenix, Inc.Inventor: Ivan N. Rich
-
Patent number: 7354729Abstract: The present invention relates generally to high-throughput assay methods that determine the proliferative status of hematopoietic stem and progenitor cells. The present invention further relates to high-throughput assays for screening compounds that modulate the growth of hematopoietic stem and progenitor cells and for identifying subpopulations thereof that are suitable for transplantation. The assay of the present invention is particularly useful for quality control and monitoring of the growth potential in the stem cell transplant setting and would provide improved control over the reconstitution phase of transplanted cells.Type: GrantFiled: January 29, 2002Date of Patent: April 8, 2008Assignee: HemoGenix, Inc.Inventor: Ivan N. Rich
-
Patent number: 7354730Abstract: The present invention relates generally to kits that provide reagent mixes and instructions for the use thereof, in performing high-throughput assay methods that determine the proliferative status of isolated target cell populations. The methods measure the luminescent output derived from the intracellular ATP content of incubated target cells, and correlate the luminescence with the proliferative status of the cells. The present invention further relates to kits that provide reagent mixes and instructions for high-throughput assays methods for screening compounds that may modulate the proliferative status of a target cell population. The kits of the present invention and methods therein described may be used for determining the proliferative status of any isolated cell line or type. The kits and methods of the present invention address the need for rapid assays that determine the proliferative status of isolated hematopoietic stem and progenitor cells and of subpopulations of differentiated cells thereof.Type: GrantFiled: August 21, 2003Date of Patent: April 8, 2008Assignee: HemoGenix, Inc.Inventor: Ivan N. Rich
-
Publication number: 20040110243Abstract: The present invention relates generally to kits that provide reagent mixes and instructions for the use thereof, in performing high-throughput assay methods that determine the proliferative status of isolated target cell populations. The methods measure the luminescent output derived from the intracellular ATP content of incubated target cells, and correlate the luminescence with the proliferative status of the cells. The present invention further relates to kits that provide reagent mixes and instructions for high-throughput assays methods for screening compounds that may modulate the proliferative status of a target cell population. The kits of the present invention and methods therein described may be used for determining the proliferative status of any isolated cell line or type. The kits and methods of the present invention address the need for rapid assays that determine the proliferative status of isolated hematopoietic stem and progenitor cells and of subpopulations of differentiated cells thereof.Type: ApplicationFiled: August 21, 2003Publication date: June 10, 2004Inventor: Ivan N. Rich
-
Publication number: 20020146680Abstract: The present invention relates generally to high-throughput assay methods that determine the proliferative status of hematopoietic stem and progenitor cells. The present invention further relates to high-throughput assays for screening compounds that modulate the growth of hematopoietic stem and progenitor cells and for identifying subpopulations thereof that are suitable for transplantation. The assay of the present invention is particularly useful for quality control and monitoring of the growth potential in the stem cell transplant setting and would provide improved control over the reconstitution phase of transplanted cells.Type: ApplicationFiled: January 29, 2002Publication date: October 10, 2002Inventor: Ivan N. Rich
-
Patent number: 6355410Abstract: The Na+/H+ exchanger isoform 1 (NHE-1) is primarily responsible for the regulation of the intracellular pH (pHi). It is a ubiquitous amiloride-sensitive growth factor activatable exchanger. There is a direct correlation between the pHi and cell cycle status of normal hemopoietic and leukemic cells, with leukemic cells having a higher pHi than normal hemopoietic cells. A method is provided to sort cells by flow cytometry into subpopulations of proliferating and non-proliferating cells and to induce apoptosis in proliferating leukemic cells by inhibiting the Na+/H+ exchanger, thereby lowering the internal pHi.Type: GrantFiled: June 3, 1999Date of Patent: March 12, 2002Inventor: Ivan N Rich
-
Publication number: 20010012620Abstract: The present invention relates to simultaneously combining intracellular pH (pHI) measurements, membrane antigen expression, and cell cycle parameters to analyze proliferating cell populations. The present invention also relates to inducing a state of apoptosis in proliferating cells by decreasing the pHi by inhibiting the cellular NHE. The present invention, therefore, provides a method of identifying a subpopulation of cell in the S-phase of the cell cycle, as a function of the pHi of the cell population, and selectively isolating this subpopulation of cells. The present invention also provides a method of selectively isolating a subpopulation of cells having a cell surface antigen. The present invention further provides methods of reducing cellular proliferation by inducing cellular apoptosis in a subpopulation of proliferating cells by contacting the cells with an NHE inhibitor, thereby reducing the pH1 and inducing a state of apoptosis.Type: ApplicationFiled: February 5, 2001Publication date: August 9, 2001Inventor: Ivan N. Rich